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Abstract
Background: A few studies have indicated inverse relationships between serum ghrelin and gastric and esophageal cancers
but those associations have been restricted to specific populations, including smokers and overweight individuals. We
examined the association between ghrelin and gastroesophageal cancers and atrophic gastritis in a population-based
setting.
Methods: In total 220 gastroesophageal cancers, comprising non-cardia and cardia gastric cancer, esophageal
adenocarcinoma, esophageal squamous cell carcinoma (SCC) and age and gender-matched controls were recruited.
Serum ghrelin, pepsinogen I/II ratio (PGI/II) and anti-H.pylori IgG antibodies were measured. Relationships between ghrelin
and gastroesophageal cancers, after adjustment for PGI/II ratio, H.pylori status and smoking, were tested using logistic
regression. Furthermore, in 125 endoscopically normal volunteers, with and without histological atrophic gastritis, the
relationship with ghrelin was compared.
Results: Serum ghrelin (lowest vs. highest quintile) was inversely associated with gastric cancer: OR (95% CI) 8.71 (1.70–
44.59) for cardia and 6.58 (1.26–34.46) for non-cardia cancer. Lower serum ghrelin was also associated with esophageal SCC:
OR (95% CI) 5.69 (1.36–23.78), but not with esophageal adenocarcinoma. A similar association was observed between
gastric cancer (cardia and non-cardia) and esophageal SCC when serum ghrelin was analysed as a continuous scaled
variable. In endoscopically-normal volunteers, extensive atrophic gastritis was associated with low serum ghrelin [OR (95%
CI) 0.25 (0.10–0.64)].
Conclusion: Inverse associations between ghrelin and some gastroesophageal cancers suggest a potential role for serum
ghrelin as a biomarker of upper gastrointestinal cancers and atrophic gastritis. In areas with a high incidence of gastric and/
or esophageal cancer, screening might be more effectively targeted to individuals with low serum ghrelin in addition to the
PGI/II ratio.
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Introduction
Gastric and esophageal cancers are among the most prevalent
malignancies worldwide, claiming more than 1,000,000 lives
annually [1]. In gastric adenocarcinoma, long-term mucosal
damage associated with Helicobacter pylori (H.pylori) infection results
in a cascade of atrophic gastritis, intestinal metaplasia, and
dysplasia leading to cancer [2]. In the process of gastric
carcinogenesis, hypochlorhydria, is caused by loss of parietal cells
in atrophic gastritis and severe chronic inflammation of the gastric
body mucosa [3,4]. Concurrent loss of chief cells from deeper
gastric glands may lead to a reduction locally and in the serum of
pepsinogen I (PGI) and pepsinogen II (PGII). The serum PGI and
to a lesser extent PGII decrease during the process of atrophic
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gastritis, which prompts the use of serum PGI/II ratio as a
surrogate marker of atrophic gastritis and cancer risk [5].
As well as hydrochloric acid and pepsinogen, the gastric mucosa
secretes several other biologically active peptides and hormones.
Notably, ghrelin is a 28-amino acid peptide hormone [6], produced
predominantly by the P/D1 cells of gastric oxyntic gland and is
mainly found in the proximal stomach [7]. Ghrelin has many
biological activities, having both autocrine and paracrine roles, in
the regulation of appetite and gut motility, regulation of growth
hormone release and immunomodulation [8,9].
The functional state of the gastric mucosa and the presence of
H.pylori infection are important for carcinogenesis of both cardia
and non-cardia cancers [10,11]. Recent studies indicate altered
ghrelin expression in patients with in upper gastrointestinal
cancers, and its lower level in gastric atrophy [12] suggests that
it is a marker of gastric mucosal function. Three recent studies
have reported an inverse relationship between serum ghrelin and
the risk of upper gastrointestinal cancers [13,14,15]. However, two
of these studies nested in the Alpha-Tocopherol Beta-Carotene
Cancer Trial (ATBC) were restricted to male smokers [13,15], and
in the third study, an inverse relationship between serum ghrelin
and esophageal adenocarcinoma only seen in an overweight
subgroup of subjects [14].
In this study, we aimed to investigate relationship between
serum ghrelin and four common upper gastrointestinal cancers,
namely gastric (non-cardia and cardia) adenocarcinoma, esopha-
geal adenocarcinoma and esophageal squamous cell carcinoma
(SCC), all in a population from the Ardabil Province, Iran known
to have a high incidence of gastric cancer [16]. In addition to test
the hypothesis that ghrelin-related carcinogenesis could be linked
to atrophic gastritis, associations between various degrees of
atrophic gastritis and serum ghrelin were investigated in a group of
endoscopically normal volunteers.
Materials and Methods
Ethics statements
All subjects including potential controls gave written informed
consent according to the declaration of Helsinki. The Aras
Gastrointestinal Health Survey and the current case-control study
were both approved by the Medical Ethics Committee of Tehran
University of Medical Sciences.
Study design and setting
Patients with upper gastrointestinal cancer (cases) and controls
were drawn from a large gastroesophageal health survey,
conducted in Aras Clinic in Ardabil province north-western Iran.
Aras Clinic is a regional referral centre for the investigation,
treatment and prevention of upper gastrointestinal tract disease
throughout Ardabil province, a well-known high-risk region for
gastric cancer [16,17]. The present study used stored serum from
controls and patients diagnosed between 2005 and 2007.
Prior to endoscopy, the investigators conducted a standardized
interview with each patient and details of his/her lifestyle factors
were systematically documented. History of smoking was recorded
as numbers of cigarettes smoked per day and duration of smoking
in years. A fasting venous blood sample was collected from each
patient before endoscopy and the serum was stored at –70uC for
later serologic assessment.
A frequency-matched case control design was used with one
control for each cancer case. Controls were selected at random
from a contemporaneous group of endoscopy negative dyspeptic
patients with no identifiable peptic ulceration, gastroduodenal
erosions or tumors. Controls matched for gender, residence place
and age 64 years were interviewed for detailed lifestyle similarly
to cases and had their serum stored prior to endoscopy.
Upper gastrointestinal cancers
Of 247 patients with gastric or esophageal cancer identified
during the health survey, 27 (11%) were excluded due to
insufficient or inappropriate serum or histological samples.
Therefore, the laboratory and questionnaire data for the
remaining 220 (72 non-cardia gastric cancers, 53 cardia gastric
cancer, 36 esophageal adenocarcinoma and 59 esophageal SCC)
were analyzed in the current study. All diagnoses of gastric or
esophageal cancer were confirmed histologically through endo-
scopic and/or surgical biopsy. All histological sections were
examined by experienced gastrointestinal pathologists and re-
viewed by a lead pathologist (M.S). All pathological diagnoses met
protocol requirements in accordance with International Classifi-
Table 1. Frequency of studied risk factors in cases and their matched controls for gastric and esophageal cancers by anatomical
and histological classification.
PG I/II ratio Smoking H.pylori Histological Subtype
,2.5 (Ever) Infection Intestinal Diffuse Mixed
Gastric non-cardia
Cases (n = 72) 69.9% 33 (45.8%) 68 (94.4%) 42 (58.3%) 25 (34.7%) 5 (6.9%)
Controls (n = 72) 29.6% 20 (27.8%) 62 (86.1%) n/a n/a n/a
Gastric cardia
Cases (n = 53) 47.2% 19 (35.8%) 44 (83.0%) 34 (64.1%) 16 (30.2%) 3 (5.7%)
Controls (n = 53) 22.6% 14 (26.4%) 46 (86.8%) n/a n/a n/a
Esophageal Adenocarcinoma
Cases (n = 36) 11.1% 19 (52.8%) 23 (63.9%) 31 (86.1%) 2 (6.6%) 3 (8.3%)
Controls (n = 36) 27.8% 9 (25.0%) 31 (86.1%) n/a n/a n/a
Esophageal squamous cell carcinoma
Cases (n = 59) 49.2% 27 (45.7%) 56 (94.9%) n/a n/a n/a
Controls (n = 59) 23.7% 16 (27.1%) 53 (89.9%) n/a n/a n/a
doi:10.1371/journal.pone.0074440.t001
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cation of Disease, Oncology, version 3 (ICD-O-3) [18]. In difficult
cases, a diagnosis of cancer was made only after joint review by the
panel of pathologists. The following ICD-O-3 codes were used to
categorize the four cancer groups: for esophageal squamous cell
carcinoma, topography C15.0– C15.9, and morphology M8070/
3; for esophageal adenocarcinoma, topography C15.0– C15.7,
and morphology M8140/2, M8140/3; for gastric cardia and
esophagogastric junctional cancer topography C16.0 and mor-
phology M8140/2, M8140/3, M8144/3, and M8145/3; for
gastric non-cardia cancer topography C16.1– C16.7, and mor-
phology M8140/2, M8140/3, M8144/3, and M8145/3. The
histological subtype of gastric adenocarcinoma was classified as
intestinal, diffuse or mixed subtypes according to the original
classification introduced by Lauren [19].The similar classification
was applied to esophageal adenocarcinoma.
Atrophic gastritis
To investigate further relationship between serum ghrelin and
precancerous changes in the stomach, a group of endoscopically
normal volunteers (n = 125) were recruited in a consecutive
fashion and divided into three histologically-defined groups. These
histological groups, age and gender-balanced, were as following:
without atrophic gastritis (n = 46), with mild-moderate antral
atrophy (n= 29) and with extensive body and antral atrophy
(n = 50). Atrophic gastritis was defined as loss of glandular tissue in
the gastric mucosa and scored based on a semi-quantitative scale
recommended by the Updated Sydney System for classification
and grading of gastritis [20]. Serum ghrelin and pepsinogen
measurement were performed in these three groups with method
similar to that applied to main study subjects.
Laboratory Assessment
Aliquots of serum stored at 270 centigrade stored from cases
and controls were analyzed for total serum ghrelin, PGI, PGII and
anti H.pylori IgG antibodies. Total serum ghrelin was quantified by
radioimmunoassay using a polyclonal rabbit antibody from
Mediagnost (Reutlingen, Germany), which assesses the peptide
from its c-terminus, thus allowing valid measurements over longer
periods of preservation [21]. Ghrelin measurements were
performed according to the kit manufacturer’s instructions, on
serum specimens without any treatment. Sensitivity of the assay
was 40 pg/ml measured as 26 standard deviation of zero
standards. Manufacturer’s data indicate maximum intra-assay
and inter-assay coefficients of variation of 5.3% and 8.2%,
respectively. Serum PGI and PGII were assayed by an enzyme
immuno-sorbant assay using monoclonal antibodies to PGI and
PGII (BIOHIT diagnostics, Biohit Ltd, UK) according to the
manufacturer’s instructions. PGI and PGII values were reported in
mg/L. The PGI/II ratio was calculated and reported as a
dimensionless fraction. H.pylori status of cases and controls was
Table 2. Risk of gastric non-cardia cancer associated with serum ghrelin presented as either quintiles or continuous variable
before and after adjustment for serum PG I/II ratio, H.pylori status and smoking.
Non-adjusted Adjusted
Cases Controls OR 95% CI P value OR 95% CI P value
n (%) n (%)
Ghrelin Quintiles (pg/ml)
5th: 960–1098 3 (4.2%) 14 (19.4%) 1.00 1.00
4th: 824–957 5 (6.9%) 15 (20.8%) 1.56 0.31–7.75 0.691 1.06 0.17–6.81 0.952
3rd: 708–818 10 (13.9%) 14 (19.4%) 3.33 0.75–14.76 0.113 2.65 0.49–14.35 0.257
2nd: 579–693 17 (25.0%) 15 (20.8%) 5.60 1.35–23.23 0.018 3.63 0.70–18.78 0.124
1st: 246–570 36 (50.0%) 14 (19.4%) 12.01 2.99–48.25 ,0.001 6.58 1.26–34.46 0.026
Decreasing ghrelin as continuous variable (scaled to 159 pg/ml) 2.09 1.53–2.84 ,0.001 1.81 1.25–2.64 0.002
doi:10.1371/journal.pone.0074440.t002
Table 3. Risk of gastric cardia cancer associated with serum ghrelin presented as either quintiles or continuous variable before and
after adjustment for serum PG I/II ratio, H.pylori status and smoking.
Non-adjusted Adjusted
Cases Controls OR 95% CI P value OR 95% CI P value
n (%) n (%)
Ghrelin Quintiles (pg/ml)
5th: 984–1158 4 (7.5%) 10 (18.9%) 1.00 1.00
4th: 869–976 4 (7.5%) 11 (20.8%) 0.91 0.18–4.64 0.909 0.99 0.18–5.47 0.990
3rd: 778–864 7 (13.2%) 11 (20.8%) 1.59 0.36–7.11 0.543 2.20 0.45–10.87 0.334
2nd: 648–776 14 (26.4%) 11 (20.8%) 3.18 0.78–12.94 0.106 5.91 1.19–29.28 0.030
1st: 249–647 24 (45.3%) 10 (18.9%) 6.00 1.52–23.71 0.011 8.71 1.70–44.59 0.009
Decreasing ghrelin as continuous variable (scaled to 122 pg/ml) 1.64 1.25–2.15 0.001 1.75 1.24–2.47 0.002
doi:10.1371/journal.pone.0074440.t003
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assessed by ELISA using anti-H.pylori IgG antibody, also from
BIOHIT diagnostics, Biohit Ltd, UK. A response titre .30
enzyme-immunounits (EIU) was considered serological evidence of
H.pylori infection. A patient was considered infected with H.pylori if
at least one of the three diagnostic tests (rapid urease test, histology
and serology) was positive.
Data and Statistical Analysis
The measured values of total serum ghrelin were reported in
two formats: as quintiles (1st to 5th quintiles) and as a continuous
variable. To generate scaled continuous variable of ghrelin, the
interquartile range of ghrelin in each control group was
determined, and half of the difference was calculated [scaling
factor = (quartile 75%– quartile 25%)/2]. The ghrelin values for
all cases in each of the four cancer groups and their controls were
divided by the relevant scaling factor. Using binary logistic
regression, the relationship between each ghrelin quintile and the
four cancer groups was estimated and reported as odds ratio (OR),
95% confidence interval and related p values. In all models
containing serum ghrelin quintiles, the 5th quintile (last) was set as
the reference group. In the multivariable model, serum PGI/II
ratio, history of smoking, and H.pylori status were used as potential
confounders. H.pylori infection and status of smoking (0 = Never,
1 = smoking of $1 cigarettes per day for at least 10 years but no
more than 5 years have passed since stopping, in the case of an ex-
smoker) were analyzed as a dichotomous variable. The difference
in ghrelin and PGI/II ratio levels between groups having different
grades of atrophic gastritis was tested using the Mann-Whitney U
test. Two sided P values ,0.05 were considered statistically
significant. Statistical analyses were conducted using SPSS
statistical package version 19 (IBM Corp., NY, USA).
Results
The main characteristics of the four groups of patients with
upper gastrointestinal cancers and their matched control groups
are summarised in Table 1.
Gastric non-cardia cancer
A total of 72 patients (54 males and 18 females, mean age
67.966.4 years) with non-cardia cancer and 72 controls were
studied. Histologically, 58.3% (42/72) of cancers were of intestinal
subtype, 34.7% (25/72) of diffuse subtype and 6.9% (5/72) of
mixed subtype. An ascending pattern in the risk of cancer was
observed from the highest to the lowest quintiles of serum ghrelin
levels (Table 2). Cancer risk was maximum in patients having
ghrelin levels in the 1st quintile (#570 pg/ml) with OR =12.01
(95% CI: 2.99–48.25) compared to patients in the 5th quintile. The
inverse association observed between serum ghrelin (1st vs. 5th
quintile) and non-cardia gastric cancer diminished in strength but
Table 4. Risk of esophageal adenocarcinoma associated with serum ghrelin presented as either quintiles or continuous variable
before and after adjustment for serum PG I/II ratio, H.pylori status and smoking.
Non-adjusted Adjusted
Cases Controls OR 95% CI P value OR 95% CI P value
n (%) n (%)
Ghrelin Quintiles (pg/ml)
5th: 995–1208 10 (27.8%) 7 (19.4%) 1.00 1.00
4th: 904–992 9 (25.0%) 7 (19.4%) 0.90 0.23–3.58 0.881 0.31 0.05–1.76 0.185
3rd: 789–889 9 (25.0%) 8 (22.2%) 0.79 0.20–3.06 0.730 0.72 0.14–3.81 0.697
2nd: 631–783 6 (16.7%) 7 (19.4%) 0.60 0.14–2.58 0.492 0.41 0.06–2.67 0.352
1st: 306–617 2 (5.6%) 7 (19.4%) 0.20 0.03–1.27 0.087 0.11 0.01–1.15 0.066
Decreasing ghrelin as continuous variable (scaled to 161 pg/ml) 0.65 0.43–1.01 0.053 0.60 0.35–1.04 0.068
doi:10.1371/journal.pone.0074440.t004
Table 5. Risk of esophageal squamous cell carcinoma associated with serum ghrelin presented as either quintiles or continuous
variable before and after adjustment for serum PG I/II ratio, H.pylori status and smoking.
Non-adjusted Adjusted
Cases Controls OR 95% CI P value OR 95% CI P value
n (%) n (%)
Ghrelin Quintiles (pg/ml)
5th: 966–1098 4 (6.8%) 12 (20.3%) 1.00 1.00
4th: 847–963 5 (8.5%) 12 (20.3%) 1.15 0.24–5.39 0.863 1.52 0.28–8.18 0.629
3rd: 770–846 7 (11.9%) 12 (20.3%) 1.60 0.37–7.02 0.530 1.71 0.35–8.34 0.510
2nd: 644–769 17 (28.8%) 12 (20.3%) 3.90 1.00–15.21 0.050 4.69 1.03–21.46 0.046
1st: 246–638 26 (44.1%) 11 (18.6%) 5.96 1.57–22.60 0.009 5.69 1.36–23.78 0.017
Decreasing ghrelin as continuous variable (scaled to 141 pg/ml) 1.80 1.32–2.46 ,0.001 1.78 1.275–2.48 0.001
doi:10.1371/journal.pone.0074440.t005
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remained statistically significant after adjustment for serum PGI/II
ratio, smoking and H.pylori infection status, with OR of 6.58 (95%
CI: 1.26–34.46). The continuous variable of ghrelin (scaled to
159 pg/ml) supported the inverse relationship observed between
serum ghrelin and non-cardia gastric cancer, with OR (95% CI)
= 2.09 (1.53–2.84) and 1.81 (1.25–2.64) for decreasing level of
ghrelin before and after adjustment for serum PG I/II ratio,
smoking and H.pylori infection status, respectively.
Gastric cardia cancer
Fifty-three patients (37 males and 16 females, mean age
63.967.1 years) with cardia cancer and similar number of controls
were included in the study. Of histological subtypes, 64.2% (34/
53) of cancers were of intestinal subtype, 30.2% (16/53) of diffuse
subtype and 5.7% (5/53) of mixed or undifferentiated subtype.
Similar to non-cardia cancer but to a lesser extent, an increasing
cancer risk was observed with decreasing levels of ghrelin (Table 3).
The risk was maximum in patients having ghrelin levels in the 1st
quintile (#647 pg/ml) than patients in the 5th quintile (984–
1158 pg/ml), with OR=6.00 (95% CI: 1.52–23.71). Multivari-
able analysis, after adjustment for serum PGI/II ratio, smoking
and H.pylori infection, strengthened the inverse association
observed between serum ghrelin (1st vs. 5th quintile) and cardia
cancer, with OR (95% CI) = 8.71 (1.70–44.59). Likewise, the
continuous variable of ghrelin, scaled to 122 pg/ml, demonstrated
a positive relationship between decreasing level of serum ghrelin
and gastric cardia cancer, with OR (95 CI%) = 1.64 (1.25–2.15)
and 1.75 (1.24–2.47), before and after adjustment for serum PGI/
II ratio, smoking and H.pylori infection status, respectively.
Esophageal Adenocarcinoma
There were 36 patients with esophageal adenocarcinoma with
mean age of 63.4 (64.2) years and an obvious pattern of male-
predominance (26 males and 10 females). Histologically, 92% (33/
36) were of intestinal subtype, except for two cases of diffuse
subtype and one mixed subtype. None of the serum ghrelin
quintiles were associated with esophageal adenocarcinoma in
either univariable or multivariable analysis, but there was marginal
inverse relationship seen between decreasing ghrelin level as a
continuous variable and risk of esophageal adenocarcinoma, being
OR (95% CI) of 0.65 (0.43–1.01) and 0.60 (0.35–1.04) in
univariable and multivariable analyses, respectively (Table 4).
Esophageal Squamous Cell Carcinoma
There were 59 patients (36 males and 23 females) with
esophageal squamous cell carcinoma and their mean (SD) age
was 65.7 (5.3) years. Anatomically, 58% (34/59) of tumors were
located in the middle third, 32% (19/59) in the upper third and
only 10% (6/59) in the lower third of esophagus. Serum ghrelin
level was inversely associated with presence of cancer, with the
highest occurrence being observed in patients with ghrelin levels in
the 1st quintile versus those in the 5th quintile, OR (95% CI)
= 5.96 (1.57–22.60). The cancer risk remained essentially
unchanged after adjustment for serum PGI/II ratio, H.pylori
infection and smoking. With ghrelin as continuous variable, a
similar positive association was observed between decreasing level
of ghrelin and esophageal squamous cell carcinoma with both
univariable and multivariable analyses (Table 5).
Ghrelin and Atrophic Gastritis
Total serum ghrelin was highest in the group without atrophic
gastritis (Med:925, IQR:209), lowest in the group with extensive
atrophic gastritis (Med:602, IQR:218) and antral atrophic gastritis
(Med:778, IQR:158) in-between the two. Both groups with
atrophy (antral and extensive) had significantly lower ghrelin level
compared to the non-atrophic group (p values ,0.01). Similar to
ghrelin, PGI/II ratio was also highest in the group without
atrophy, and lowest in the group with extensive atrophy but the
difference between non-atrophic and antral atrophic groups was
not statistically significant (p value = 0.211) (Figure 1). Further-
more, total serum ghrelin was correlated with serum PGI/II ratio,
but the magnitude of the correlation was not large (CC=0.40, p
value ,0.01).
Logistic regression model was used to compare the magnitude
of association between extensive atrophic gastritis and either scaled
ghrelin or PGI/II ratio. Between the two variables, scaled ghrelin
but not PGI/II ratio showed a significant inverse association with
extensive atrophic gastritis [(OR=0.254, 95%CI: 0.101–0.638), p
value = 0.004].
Discussion
In this case-control study, we found statistically significant
inverse relationships between serum ghrelin and gastric non-cardia
cancer, gastric cardia cancer and esophageal squamous cell
carcinoma (SCC). The relationship between ghrelin and gastric
adenocarcinoma, however, was not statistically significant. More-
over, we found that cancer-free individuals with extensive atrophic
gastritis had significantly lower serum ghrelin.
Only a few published studies examined relationships between
serum ghrelin levels and gastric [15,22] or esophageal [13,14]
cancer. All of these studies required further investigations in
different populations to confirm their findings, and had limitations
in sample size. The current study provides robust evidence of the
role of serum ghrelin level, as a surrogate marker of gastric
mucosal function, in three common types of upper gastrointestinal
cancers in a high-risk population residing in Ardabil province,
Iran.
In the current study, both in quintiles and scaled continuous
variable, serum ghrelin levels were observed to have an inverse
relationship with the risk of non-cardia gastric cancer. This is
consistent with findings of Murphy et al. [15], the only study in
which the location of non-cardia gastric cancer has been clearly
defined. The negative association between serum ghrelin level and
non-cardia gastric cancer remained significant after adjustments
Figure 1. Association between histological atrophic gastritis
limited to antrum (antral) or extended to body (extensive) and
serum ghrelin versus serum PGI/II ratio, all statistical compar-
isons tested by Mann-Whitney U test.
doi:10.1371/journal.pone.0074440.g001
Serum Ghrelin and Upper Gastrointestinal Cancer
PLOS ONE | www.plosone.org 5 September 2013 | Volume 8 | Issue 9 | e74440
for PGI/II ratio, smoking and H.pylori infection, indicating the
independent nature of the observed inverse association.
The mechanism underlying the inverse relationship between
non-cardia gastric cancer and serum ghrelin levels has not been
thoroughly investigated by previous studies. Ghrelin is produced
by several different tissues in the human body (including
hypothalamus, pituitary, small and large intestine and pancreas),
but its main source is the gastric oxyntic epithelium, largely in
unacetylated form [7]. The ghrelin immunoreactive cells are
located close to parietal cells [23], and atrophic gastritis is thought
to involve loss of ghrelin-producing cells. This hypothesis has been
supported by studies showing lower levels of ghrelin in patients
with atrophic gastritis [24–25]. A strong association between
ghrelin and extensive gastric atrophy in our study supports the
suggested mechanism. The profound and long-term reduction of
the serum ghrelin following resective gastric bypass is another
evidence of gastric body mucosa serving as the main source of
ghrelin which is eliminated by surgical resection rather than
atrophic gastritis [26]. Moreover, long standing chronic inflam-
mation of gastric mucosa with or without atrophic changes during
H.pylori infection is associated with considerable reduction of
fundic ghrelin mRNA expression and plasma ghrelin concentra-
tion [27,28]. In patients with more advanced gastric cancer,
several factors including ghrelin, leptin, adiponectin and insulin-
like growth factor -I (IGF-I) are involved in the cachexia [29].
As with non-cardia cancers, an increasing risk of gastric cardia
cancer with decreasing levels of serum ghrelin was also observed.
Patients with gastric cardia cancers in our study are in part
comparable to patients with esophago-gastric junction cancer in
the study by Murphy et al. [15], but tumors of the distal esophagus
are not covered by our definition of cardia cancer. The relatively
weaker inverse relationship of ghrelin level in cardia vs. non-cardia
gastric cancer is consistent with the null association observed
between esophageal adenocarcinoma and ghrelin levels in our
study.
The absence of a statistically significant relationship between
serum ghrelin and esophageal adenocarcinoma was another
important finding. In a nested case-control study by de Martel
et al. [14], a very high concentration (.3200 pg/ml) of serum
ghrelin was associated with a lower risk of esophageal adenocar-
cinoma, a finding was unexpected even to the authors themselves.
They realized that the inverse association is evident only in
overweight subjects with body mass index (BMI) .25. We
attempted to replicate their subgroup analysis, but due to the
retrospective nature of our study, BMI data was only available in
half of the cancer cases, all with BMI between 20.5 and 24.6
except for one with BMI of 25.8 (analysis not shown). Therefore,
our observations and that of de Martel’s study should be
interpreted with caution since it may not represent the real nature
of association between ghrelin levels and esophageal adenocarci-
noma. In addition, considering marked inverse association
between esophageal adenocarcinoma and atrophic gastritis [30],
the lack of association (or a non-significant inverse association)
between esophageal adenocarcinoma and serum ghrelin in the
current study is an expected finding.
In order to improve our understanding of ghrelin’s association
with a wide range of upper gastrointestinal cancers, we included a
group of patients with esophageal squamous cell carcinoma. The
inverse relationship between ghrelin levels, both in quintiles and in
continuous variable, with squamous cell carcinoma was evident in
both univariable and multivariable analyses. Similar results were
reported by Murphy et al. [13]; however in their study, they have
only adjusted the association to PGI but not PGI/II ratio, as a
marker of atrophic gastritis.
Many studies [31–38] have reported a greater risk of esophageal
squamous cell carcinoma in subjects with atrophic gastritis.
Although serum PGI/II ratio has been used as a surrogate marker
of atrophic gastritis in most studies [31–36], the positive
association between the two has been confirmed even if the
presence of atrophic gastritis is determined by histological [37] or
endoscopic methods [38], indicating robustness of the association.
If the inverse relationship between serum ghrelin and esophageal
squamous cell carcinoma is attributed to the presence of atrophic
gastritis, why is the association independent from PG/II ratio in our
study and fromPGI inMurphy’s [13] study? Both serumghrelin and
PGI/II ratio (and PGI to a lesser extent) are serological markers of
atrophic gastritis, but they may not represent the same changes
during the process of oxyntic glands destruction in atrophic gastritis,
because they are produced by different cell types at different depths
within the oxyntic glands. An unknowndegree of sampling error and
inaccurate measurement due to potential circadian rhythm, in the
case of serumPGI/II ratio and even serum ghrelinmay explain their
independent association with the atrophic gastritis in the process of
cancer genesis. Moreover, exact mechanisms responsible for the
excess risk of esophageal squamous cell carcinoma in subjects with
atrophic gastritis are not clear, although high levels of nitrosamine
compounds or other carcinogenic products of bacterial overgrowth
in the stomach have been proposed as a potential pathway [39].
The results of the current study provide evidence for serum
ghrelin being a surrogate marker of gastric mucosal function in
upper gastrointestinal cancers in a population setting different
from the other three studies mentioned above [13,14,15]. The
homogenous distribution of H.pylori infection and smoking rates in
the control group and their similarity to general residents of the
target area allowed them being acceptable representatives of the
general population [40–41]. Our study does have some limitations,
primarily the small number of esophageal adenocarcinoma cases,
deficient information on BMI and addressing limited number of
environmental risk variables. Additional measurement of acylated
vs. unacylated forms of ghrelin may be ideal due to their
differential effect and this should be considered in the future study
design.
In conclusion, further evidence presented in the current
comprehensive study supports the role of ghrelin as a marker of
gastric mucosal alterations in upper gastrointestinal cancers in a
population who are known to be at high risk of gastric cancer.
These results provide further insight into the pathogenesis of upper
gastrointestinal cancers, and may provoke more detailed investi-
gations leading to identification of a panel of diagnostic serological
markers applicable to surveillance programmes.
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